SSA
NGNE icon

Schonfeld Strategic Advisors’s Neurogene NGNE Stock Holding History

Schonfeld Strategic Advisors’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-27,894
Closed -$575K – 2510
2025
Q4 		$575K Buy
+27,894
New +$694K ﹤0.01% 1342
2025
Q1 		– Sell
-9,189
Closed -$210K – 2403
2024
Q4 		$210K Sell
9,189
-23,477
-72% -$874K ﹤0.01% 1752
2024
Q3 		$1.37M Buy
32,666
+18,366
+128% +$712K 0.01% 1043
2024
Q2 		$520K Buy
14,300
+8,395
+142% +$296K ﹤0.01% 1468
2024
Q1 		$301K Buy
+5,905
New +$197K ﹤0.01% 1643

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Schonfeld Strategic Advisors's NGNE Position: Q1 2026 in Review

Schonfeld Strategic Advisors sold out of Neurogene (NGNE) in Q1 2026, closing a stake of 27,894 shares — an estimated $575K sold.

Schonfeld Strategic Advisors first reported a position in NGNE in Q1 2024 and held it in 5 quarters. The position peaked at $1.37M in Q3 2024. 96 funds tracked by Wall St. Rank hold NGNE as of Q1 2026.

  • Schonfeld Strategic Advisors reported no remaining Neurogene position as of Q1 2026 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 27,894 Neurogene shares in Q1 2026, an estimated $575K.
  • Schonfeld Strategic Advisors first reported a position in Neurogene in Q1 2024 and held it in 5 quarters.
  • Schonfeld Strategic Advisors's Neurogene position peaked at $1.37M in Q3 2024.
  • 96 funds tracked by Wall St. Rank held Neurogene as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.